LONDON – Abingworth has exceeded ambitions with its latest fund, closing Bioventures VI at £225 million (US$375 million), £25 million over target.
The fund, London-based Abingworth’s 10th in life sciences, will invest in companies at all stages of development, including early and late-stage private deals, venture investments in public equities (VIPE), venture growth and public equities.
Investment size will range from £5 million to £20 million per company, across all rounds of financing.
Stephen Bunting, managing partner, expects to make 15-20 investments over the next three years.
“There are lots of opportunities, though the number of really good ones is the issue,” he told BioWorld Today. The first four investments from the fund have been announced, and two further deals are about to close.
In total, Bunting expects to seal six deals this year and said that currently, “there is a good environment for